Lancemaside A inhibits microglial activation via modulation of JNK signaling pathway

Biochemical and Biophysical Research Communications

Volumn 431, Issue 3, 2013, Pages 369-375

  Jeong, Yeon Hui ^a   Jung, Ji Sun ^a   Le, Thi Kim Van ^b   Kim, Dong Hyun ^b   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

JNK signaling pathway; Lancemaside A; Microglia; Neuroinflammation; Neuroprotection

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOOXYGENASE 2; CYTOKINE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; JANUS KINASE; LANCEMASIDE A; LIPOPOLYSACCHARIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR AP 1; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CELL VIABILITY; CODONOPSIS; CODONOPSIS LANCEOLATA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MICROGLIA; MOLECULAR MECHANICS; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICE; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; SAPONINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

CODONOPSIS LANCEOLATA;

EID: 84873716660     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.049     Document Type: Article

References (28)

1. Tremblay M.è., Stevens B., Sierra A., Wake H., Bessis A., Nimmerjahn A. The role of microglia in the healthy brain. J. Neurosci. 2011, 31:16064-16069.
2. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
3. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
4. Komoto N., Ichikawa M., Ohta S., Nakano D., Nishihama T., Ushijima M., Kodera Y., Hayama M., Shirota O., Sekita S., Kuroyanagi M. Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. J. Nat. Med. 2010, 64:321-329.
5. Joh E.H., Kim D.H. A sensitive liquid chromatography-electrospray tandem mass spectrometric method for lancemaside A and its metabolites in plasma and a pharmacokinetic study in mice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:1875-1880.
6. Joh E.H., Lee I.A., Han S.J., Chae S.J., Kim D.H. Lancemaside A ameliorates colitis by inhibiting NF-κB activation in TNBS-induced colitis mice. Int. J. Colorectal. Dis. 2010, 25:545-551.
7. Joh E.H., Kim D.H. Lancemaside A inhibits lipopolysaccharide-induced inflammation by targeting LPS/TLR4 complex. J. Cell. Biochem. 2010, 111:865-871.
8. Jung I.H., Jang S.E., Joh E.H., Chung J., Han M.J., Kim D.H. Lancemaside A isolated from Codonopsis lanceolata and its metabolite echinocystic acid ameliorate scopolamine-induced memory and learning deficits in mice. Phytomedicine 2012, 20:84-88.
9. Jung J.S., Shin J.A., Park E.M., Lee J.E., Kang Y.S., Min S.W., Kim D.H., Hyun J.W., Shin C.Y., Kim H.S. Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide-stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression. J. Neurochem. 2010, 115:1668-1680.
10. Tufekci K.U., Genc S., Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis. 2011, 487450.
11. Gao H.M., Zhou H., Hong J.S. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci. 2012, 33:295-303.
12. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
13. Keum Y.S. Regulation of Nrf2-mediated phase II detoxification and anti-oxidant genes. Biomol. Ther. 2012, 20:144-151.
14. Espel E. The role of the AU-rich elements of mRNAs in controlling translation. Semin. Cell Dev. Biol. 2005, 16:59-67.
15. Swantek J.L., Cobb M.H., Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: gluococorticoid inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell Biol. 1997, 17:6274-6282.
16. Kaminska B. MAPK signaling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochem. Biophys. Acta 2005, 1754:253-262.
17. Kaminska B., Gozdz A., Zawadzka M., Ellert-Miklaszewska A., Lipko M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. 2009, 292:1902-1913.
18. Mehan S., Meena H., Sharma D., Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J. Mol. Neurosci. 2011, 43:376-390.
19. Sugino T., Nozaki K., Takagi Y., Hattori I., Hashimoto N., Moriguchi T., Nishida E. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J. Neurosci. 2000, 20:4506-4514.
20. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., White R.F., McVey M.J., Legos J.J., Erhardt J.A., Nelson A.H., Ohlstein E.H., Hunter A.J., Ward K., Smith B.R., Adams J.L., Parsons A.A. SB239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. 2001, 296:312-321.
21. Piao C.S., Kim J.B., Han P.L., Lee J.K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J. Neurosci. Res. 2003, 73:537-544.
22. Munoz L., Ammit A.J. P38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacol. 2010, 58:561-568.
23. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostrial dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 1999, 288:421-427.
24. Guan Q.H., Pie D.S., Zhang Q.G., Hao Z.B., Xu T.L., Zhang G.Y. The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampus CA1 via nuclear and non-nuclear pathways. Brain Res. 2005, 1035:51-59.
25. Waetzig V., Czeloth K., Hidding U., Mielke K., Kanzow M., Brecht S., Goetz M., Lucius R., Herdegen T., Hanisch U.K. C-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005, 50:235-246.
26. Huo Y., Rangarajan P., Ling E.A., Dheen S.T. Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia. BMC Neurosci. 2011, 12:49.
27. Wang X.J., Zhang S., Yan Z.Q., Zhao Y.X., Zhou H.Y., Wang Y., Lu G.Q., Zhang J.D. Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic degeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Rad. Biol. Med. 2011, 50:1094-1106.
28. Dang P.M., Stensballe A., Boussetta T., Raad H., Dewas C., Kroviarski Y., Hayem G., Jensen O.N., Gougerot-Pocidalo M.A., El-Benna J. A specific p47phox-serine phosphorylated by convergent MAPKs mediated neutrophil NADPH oxidase priming at inflammatory sites. J. Clin. Invest. 2006, 116:2033-2043.